Granules India arm gets 5 USFDA observations for Hyderabad facility
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2025-12-20 07:08 GMT | Update On 2025-12-20 07:08 GMT
Advertisement
Telangana: Granules India has announced that the U.S. Food and Drug Administration (FDA) has concluded an inspection with five observations at the Hyderabad facility of Granules Life Sciences, a wholly owned subsidiary of the Company.
The Good Manufacturing Practices (GMP) and Prior Approval Inspection was conducted from 15th to 19th December 2025.
The five observations were related to procedural requirements. None of these observations are associated with data integrity or product safety.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.